EN
Home/Answers/Liver enzymes
ALLAll countries Side effects and safety

Can tirzepatide or semaglutide raise your liver enzymes?

What we checked14 sources, each one opened and linked to the sentence it supportsLast checked Nov 16, 2026 · Next review due Nov 16, 2027 · How we write
The short answer

Sometimes. The US Wegovy label reports ALT rises of five times normal or more in 3% of teenagers on semaglutide, some linked to gallstones. The US Zepbound (tirzepatide) label lists none. In fatty liver trials, both medicines improved the liver more often than placebo. Gallstones, other medicines, supplements and intense exercise can also affect results.

Do the labels list raised liver enzymes?

The US Wegovy label does, mainly for teenagers. In one trial, 3% of teenagers on semaglutide had large ALT rises, against none on placebo.1

In a weight-loss trial in young people aged 12 and over, ALT, a liver enzyme, rose to at least five times the upper limit of normal in 4 teenagers on Wegovy (3%), against 0% on placebo. The label says some of these rises, in ALT and in AST, came with other factors such as gallstones. In the adult heart trial, bilirubin rose to at least three times normal in 0.3% on Wegovy against 0.2% on placebo.1

The US Zepbound label lists no liver test changes for tirzepatide, and the side-effect section of the EU Mounjaro product information (SmPC) lists none either.214 A 2024 case report attributed one woman’s raised liver enzymes to tirzepatide and said no such case had been reported before.4

Both medicines can cause gallbladder problems, including gallstones.12 The US Zepbound label says a suspected inflamed gallbladder calls for gallbladder tests and follow-up.2

Can they lower liver enzymes instead?

In fatty liver with inflammation (MASH), the trial behind Wegovy’s US approval saw a trend towards larger ALT and AST falls than on placebo from week 12.1

The trial, called ESSENCE on the UK label, reported its 72-week results for 800 adults with MASH and moderate to advanced scarring (fibrosis stage F2 or F3).18 At 72 weeks, liver biopsies showed the inflammation had cleared without worse scarring in 63% on Wegovy injections, against 34% on placebo. Scarring improved by at least one stage in 37%, against 22%. Average weight loss was 10.5%, against 2%.1

The US label approves Wegovy injections for this use in adults without cirrhosis, under accelerated approval that may depend on a confirmatory trial. It says Wegovy tablets have not been shown to be safe and effective in MASH.1

For tirzepatide, a 52-week trial of 190 people with MASH and F2 or F3 fibrosis found MASH cleared without worse scarring in 44%, 56% and 62% on the 5, 10 and 15 mg doses, against 10% on placebo. The authors say larger and longer trials are needed.3 The US Zepbound label does not list MASH as a use.2

The risks, in brief Nausea, vomiting, diarrhoea and constipation are common, mostly while the dose is being raised. The US Wegovy and Zepbound labels also warn of gallbladder problems, including gallstones, and an inflamed pancreas (pancreatitis).12 Side effects and risks (US guide)

What else can raise liver enzymes?

MedlinePlus, from the US National Library of Medicine, says a high ALT does not always mean a condition that needs treatment.6

It lists hepatitis, infection, other liver diseases and some medicines, such as cholesterol or pain medicines, as causes of liver damage that raise ALT. Age, sex, weight, dietary supplements, intense exercise and the menstrual cycle can also affect the result.6

Fatty liver itself does not usually cause symptoms, the NHS says, and is usually found when tests are done for another reason. A GP will ask about alcohol, and may arrange more blood tests and sometimes an ultrasound to rule out other causes and check for damage.7 Our US guide to GLP-1 side effects covers gallbladder and other risks.

Fast weight loss may nudge ALT up at first. In a 2020 study of a meal-replacement diet in adults with severe obesity, median ALT rose from 28 to 40 iu/L after 2 weeks, then fell to 21 by 24 weeks. That study used a diet, not a GLP-1 medicine.5

What do people on GLP-1 medicines report about liver enzymes?

From public patient forums: 42 Reddit threads in r/Zepbound, r/Mounjaro, r/Semaglutide, r/glp1, r/WegovyWeightLoss and r/WegovyPillWeightLoss, read from October 2025 to October 2026. Personal reports, not medical evidence.

What people describe

  • Matches the US Wegovy label Many say raised ALT or AST turned up on routine blood tests, mostly on tirzepatide. The US Wegovy label records large ALT rises in a trial of teenagers on semaglutide, and a 2024 case report linked raised enzymes to tirzepatide.14
  • Matches a diet study Many say a rise settled on a repeat test, often while staying on the medicine. A 2020 diet study saw an early ALT rise with fast weight loss, then a fall.5
  • Matches MedlinePlus Many found another cause, most often a statin or a supplement. MedlinePlus lists cholesterol medicines and supplements among things that affect ALT.6
  • Matches the US Wegovy label Several linked their raised numbers to gallstones. The label ties some ALT and AST rises to gallstones.1
  • Matches the US Wegovy label Many say fatty liver or raised enzymes improved on the medicine. In the label’s MASH trial, ALT and AST tended to fall more than on placebo.1

Advice people share

  • Matches MedlinePlus Many suggest going through every medicine, supplement and drink with the doctor. MedlinePlus says to tell your provider everything you take.6
  • Matches the NHS Many suggest repeating the test, and a scan if numbers stay high. The NHS describes more blood tests and sometimes an ultrasound.7
  • Matches the US Zepbound label Several suggest asking for a gallbladder check, especially with upper tummy pain. The label calls for gallbladder tests when inflammation is suspected.2
  • Label says otherwise Several replies call large rises normal and temporary, or say the medicine cannot be the cause. The US Wegovy label links some rises to gallstones, and a 2024 case report attributed raised enzymes to tirzepatide.14
  • Label says otherwise Several describe taking ‘detox’ supplements to lower their numbers. MedlinePlus lists dietary supplements among things that can affect ALT, and says to tell your provider everything you take.6

In your country

The trial figures above come from US labels. Whether Wegovy is approved for MASH, and what labels say about severe liver impairment, differs between countries.

Australia

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.

Label: The Australian Wegovy Product Information lists non-cirrhotic MASH with F2 to F3 fibrosis as a use, under provisional approval. It needs no dose change in liver impairment but advises caution in severe impairment.10

Emergency number: 000

Wegovy for fatty liver (MASH) in Australia

Canada

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.

Label: The Canadian Wegovy monograph lists non-cirrhotic MASH with F2 to F3 fibrosis as a use, authorised with conditions that may depend on a confirmatory trial.9

Emergency number: 911

Wegovy for heart and liver in Canada

France

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).

Label: The EU Wegovy SmPC we opened does not list MASH as a use, and says semaglutide is not recommended in severe liver impairment.11 The EU Mounjaro SmPC advises caution in severe liver impairment.14

Emergency number: 15 or 112

Side effects guide for France

Germany

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.

Label: The EU Wegovy SmPC we opened does not list MASH as a use, and says semaglutide is not recommended in severe liver impairment.11 The EU Mounjaro SmPC advises caution in severe liver impairment.14

Emergency number: 112

Side effects guide for Germany

India

Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).

Label: We could not find an Indian label to open, so this page relies on the US labels cited above. A July 2026 press report says India’s regulator, CDSCO, approved Wegovy for non-cirrhotic MASH with moderate to advanced fibrosis.12

Emergency number: 112

Fatty liver and GLP-1 medicines in India

Saudi Arabia

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.

Label: We could not find a Saudi label to open, so this page relies on the US labels cited above.

Emergency number: 997 or 911

Side effects guide for Saudi Arabia

United Arab Emirates

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.

Label: We could not find a UAE label to open, so this page relies on the US labels cited above.

Emergency number: 998 for an ambulance, or 999

Side effects guide for the UAE

United Kingdom

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.

Label: The UK Wegovy SmPC lists non-cirrhotic MASH with F2 to F3 fibrosis as a use. It needs no dose change in liver impairment but advises caution in severe impairment.8

Emergency number: 999

Side effects guide for the UK

United States

Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).

Label: This page uses the US Wegovy and Zepbound labels, so the US figures above apply directly. The US Mounjaro (diabetes) label was not checked for this page.

Emergency number: 911

Wegovy for heart and fatty liver (MASH) in the US

Get help now: call your local emergency number for any sudden or severe pain, upper abdominal or chest pain or pressure lasting two minutes or more, severe or persistent vomiting, or fainting.13 Emergency numbers: 911 in the US and Canada, 999 in the UK, 998 or 999 in the UAE, 000 in Australia, 112 in India and Germany, 15 or 112 in France, 997 or 911 in Saudi Arabia.

Contact your prescriber or a doctor right away if you have pain in your upper stomach, fever, yellowing of the skin or eyes, or pale, clay-coloured stools.12

Read the full picture

Related questions

Did this answer your question?

Sources

  1. US Wegovy (semaglutide) prescribing information and Medication Guide, Novo Nordisk, revised June 2026. Sections 1, 6.1, 14.4 and 17. novo-pi.com
  2. US Zepbound (tirzepatide) prescribing information and Medication Guide, Eli Lilly, revised August 2026. Sections 1, 5.4, 6, 8.7 and 17. uspl.lilly.com
  3. Loomba R, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis (SYNERGY-NASH). N Engl J Med 2024;391:299-310. Abstract. doi.org
  4. Sohal A, Casanova L, Kowdley KV. A rare case of tirzepatide-induced hepatotoxicity. ACG Case Rep J 2024;11:e01484. Abstract. doi.org
  5. Abdalgwad R, et al. Changes in alanine aminotransferase in adults with severe and complicated obesity during a milk-based meal replacement programme. Nutr Metab (Lond) 2020;17:87. Abstract. doi.org
  6. MedlinePlus, US National Library of Medicine. ALT blood test. Updated November 5, 2024. medlineplus.gov
  7. NHS. Non-alcoholic fatty liver disease (NAFLD). nhs.uk
  8. UK Wegovy FlexTouch (semaglutide) Summary of Product Characteristics, emc. Sections 4.1, 4.2 and 5.1. medicines.org.uk
  9. Canadian Wegovy (semaglutide) Product Monograph, Health Canada. Indications. pdf.hres.ca
  10. Australian Wegovy (semaglutide) Product Information. Sections 4.1 and 4.2. medsinfo.com.au
  11. EU Wegovy (semaglutide) Summary of Product Characteristics, European Medicines Agency. Sections 4.1, 4.2 and 4.4. ema.europa.eu
  12. Business Standard. Novo Nordisk’s Wegovy gets CDSCO nod for fatty liver disease indication. July 2026. business-standard.com
  13. American College of Emergency Physicians. Know When to Go to the ER. emergencyphysicians.org
  14. EU Mounjaro (tirzepatide) Summary of Product Characteristics, European Medicines Agency. Sections 4.2 and 4.8. ema.europa.eu

Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, all checked between Nov 9 and Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write